Telesis Bio Statistics
Total Valuation
Telesis Bio has a market cap or net worth of $6.69 million. The enterprise value is $27.11 million.
| Market Cap | 6.69M |
| Enterprise Value | 27.11M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Telesis Bio has 1.67 million shares outstanding. The number of shares has increased by 1.40% in one year.
| Shares Outstanding | 1.67M |
| Shares Change (YoY) | +1.40% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 37.68% |
| Owned by Institutions (%) | 36.74% |
| Float | 521,952 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.27 |
| Forward PS | 0.28 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.65
| Current Ratio | 3.65 |
| Quick Ratio | 2.92 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.71 |
Financial Efficiency
Return on equity (ROE) is -500.20% and return on invested capital (ROIC) is -158.13%.
| Return on Equity (ROE) | -500.20% |
| Return on Assets (ROA) | -53.40% |
| Return on Capital (ROIC) | -158.13% |
| Revenue Per Employee | $167,571 |
| Profits Per Employee | -$320,592 |
| Employee Count | 147 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 3.27 |
Taxes
In the past 12 months, Telesis Bio has paid $23,000 in taxes.
| Income Tax | 23,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.88% in the last 52 weeks. The beta is 1.74, so Telesis Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.74 |
| 52-Week Price Change | -84.88% |
| 50-Day Moving Average | 4.00 |
| 200-Day Moving Average | 7.61 |
| Relative Strength Index (RSI) | 50.91 |
| Average Volume (20 Days) | 61,019 |
Short Selling Information
The latest short interest is 43,105, so 2.58% of the outstanding shares have been sold short.
| Short Interest | 43,105 |
| Short Previous Month | 56,867 |
| Short % of Shares Out | 2.58% |
| Short % of Float | 8.26% |
| Short Ratio (days to cover) | 1.17 |
Income Statement
In the last 12 months, Telesis Bio had revenue of $24.63 million and -$47.13 million in losses. Loss per share was -$28.20.
| Revenue | 24.63M |
| Gross Profit | 14.89M |
| Operating Income | -44.09M |
| Pretax Income | -45.22M |
| Net Income | -47.13M |
| EBITDA | -38.01M |
| EBIT | -42.15M |
| Loss Per Share | -$28.20 |
Balance Sheet
The company has $15.70 million in cash and $36.12 million in debt, giving a net cash position of -$20.42 million or -$12.21 per share.
| Cash & Cash Equivalents | 15.70M |
| Total Debt | 36.12M |
| Net Cash | -20.42M |
| Net Cash Per Share | -$12.21 |
| Equity (Book Value) | -8.24M |
| Book Value Per Share | -4.92 |
| Working Capital | 16.98M |
Cash Flow
In the last 12 months, operating cash flow was -$26.74 million and capital expenditures -$2.00 million, giving a free cash flow of -$28.73 million.
| Operating Cash Flow | -26.74M |
| Capital Expenditures | -2.00M |
| Free Cash Flow | -28.73M |
| FCF Per Share | -$17.20 |
Margins
Gross margin is 60.43%, with operating and profit margins of -178.98% and -191.32%.
| Gross Margin | 60.43% |
| Operating Margin | -178.98% |
| Pretax Margin | -183.57% |
| Profit Margin | -191.32% |
| EBITDA Margin | -154.30% |
| EBIT Margin | -171.10% |
| FCF Margin | -116.64% |
Dividends & Yields
Telesis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.40% |
| Shareholder Yield | -1.40% |
| Earnings Yield | -704.48% |
| FCF Yield | -429.51% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 9, 2024. It was a reverse split with a ratio of 1:18.
| Last Split Date | May 9, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:18 |
Scores
Telesis Bio has an Altman Z-Score of -5.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.15 |
| Piotroski F-Score | 3 |